Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-AGT01 RVR in healthy volunteers
NCT06675565Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ALN-AGT01 RVR with Placebo (2 arms). Primary endpoint: Adverse Events at 3 months. Started Nov 2024; status: completed.
02
Drugs
zilebesiran
Beyond the preview
Go deeper on NCT06675565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675565.